Navigation Links
Tarsa Therapeutics Signs Commercial Supply Agreement for its Ostora™ Oral Calcitonin Product With QS Pharma
Date:3/21/2012

PHILADELPHIA, March 21, 2012 /PRNewswire/ -- Tarsa Therapeutics today announced it has entered into a commercial supply agreement with QS Pharma for the bulk manufacture of its OSTORA™ oral recombinant salmon calcitonin tablet.  The OSTORA tablets, which will be manufactured in QS Pharma's state-of-the-art facility in Pennsylvania, will be used for product launch and commercial sale.

This new agreement builds on the continuing collaboration between Tarsa and QS Pharma that began with an initial agreement for small-scale development batches and progressed to the scale-up and validation activities currently underway.

Following positive Phase III results and a successful pre-NDA meeting with the FDA, Tarsa is preparing to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) later this year for its OSTORA tablet for the treatment of postmenopausal osteoporosis.  Tarsa reported positive efficacy and safety results from its Phase III ORACAL trial showing that OSTORA achieved all the efficacy endpoints and demonstrated statistically significant superiority to both placebo and nasal calcitonin spray in increasing bone mineral density at the lumbar spine after 48 weeks.  The safety profile of OSTORA did not substantially differ from nasal calcitonin or placebo.  As the first once-daily oral calcitonin tablet expected to reach the market, OSTORA has the potential to offer patients and physicians the proven safety and efficacy of calcitonin with the advantage of significantly easier administration. 

"This production agreement with QS Pharma is timely as we prepare to submit an NDA for OSTORA later this year," noted David Brand, Chief Executive Officer of Tarsa.  "We have been impressed in our dealings to date with the QS Pharma team and are pleased to have secured a highly qualified manufacturer located just a few miles from our headquarters." 

Nutan Gangrade, President of QS Pharma commented, "This new commercial supply agreement with Tarsa Therapeutics is especially gratifying because it reflects the excellence of the work we have conducted for the company during the clinical development of OSTORA.  We appreciate their continuing confidence and look forward to the opportunity to support the successful commercialization of the first-ever oral calcitonin product expected to reach the market."

Tarsa's oral calcitonin is also being assessed in a one-year double-blind Phase II study comparing the OSTORA tablet to placebo in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  The study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population. 

Tarsa is developing its OSTORA oral calcitonin under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.

About QS Pharma
QS Pharma, located near Philadelphia in Boothwyn, PA, provides a broad range of contract development/research and clinical/commercial manufacturing services for pharmaceutical and biopharmaceutical companies worldwide.  Founded on the tenet of Quality with Speed™, QS Pharma has extensive pharmaceutical product development expertise and knowledge.  Its facility consists of over 43,000 sq ft of analytical laboratories and drug product manufacturing space with state-of-the-art cGMP manufacturing suites that can accommodate batch sizes ranging from <1kg to over 300kg.  For more information, see www.qspharma.com.

About Tarsa Therapeutics
Tarsa Therapeutics is developing OSTORA™, a novel oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.  OSTORA is expected to be the first approved oral calcitonin, a natural hormone with a long history of safety and efficacy as an osteoporosis therapy.  Availability of an oral calcitonin for osteoporosis is expected to generate wider use as doctors and patients are seeking new options that are safe and effective.  Tarsa has reported positive efficacy and safety results from a Phase III trial of OSTORA in the treatment of postmenopausal osteoporosis, and a Phase II osteoporosis prevention trial is underway.  The company is preparing to submit marketing applications in the US and Europe for OSTORA as a treatment for osteoporosis. Tarsa is based in Philadelphia, PA.  For more information, visit www.tarsatherapeutics.com.

Contact:
GendeLLindheim BioCom Partners
Barbara Lindheim or Jennifer Anderson
212-584-2276
blindheim@biocompartners.com
janderson@biocompartners.com

 

 


'/>"/>
SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
2. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
3. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
4. Novation Releases Its Latest Transcatheter Cardiovascular Therapeutics Report to Help Members Understand and Prepare for New Technologies
5. Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100
6. Echo Therapeutics, Inc. Announces 2011 Financial Results
7. Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
8. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
9. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
10. ADHD Therapeutics Reviewed by NeuroPerspective
11. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... Aug. 4, 2017 The search for test ... a physician/patient consult has long been the goal of ... notable focus of the largest meeting of lab professionals ... healthcare market research firm Kalorama Information.  The firm said ... offerings or related supplies and software were at the ...
Breaking Medicine Technology:
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America Pain ... an interventional pain management physician. He brings a wealth of pain management experience ... and significant experience in spinal cord stimulation for chronic pain. , Dr. Ahmed ...
(Date:8/18/2017)... , ... August 18, 2017 , ... More than 20,000 ... Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions of ... the generous support of the Liberty community. These shoes will save lives from the ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
Breaking Medicine News(10 mins):